SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

Zentalis estimates that about half of PROC patients overexpress Cyclin E1 based on its proprietary immunohistochemistry cutoff. As of the January 13, 2025 data cutoff, the safety and tolerability ...

Zentalis reports updated DENALI trial results for azenosertib in platinum-resistant ovarian cancer, showing 6.3 months median duration of response. Updated median duration of response (mDOR) of 6. ...

Zentalis estimates that about half of PROC patients overexpress Cyclin E1 based on its proprietary immunohistochemistry cutoff. As of the January 13, 2025 data cutoff, the safety and tolerability ...

SAN DIEGO, March 15, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

Guggenheim decreased their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th.

PRELIMINARY results from the MITO 40 study suggest that Niraparib, a maintenance treatment, may offer significant benefits for patients with no residual disease after primary surgery for ovarian ...

NEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (Zentalis ...

This page features the latest news about the Zentalis Pharma share. Zentalis Pharmaceuticals Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of ...

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...